WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406632
Description: Pyridoclax, also known as MR29072, is a potent and selective Mcl-1 inhibitor. Without cytotoxic activity when administered as a single agent, pyridoclax induced apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. Bcl-xL and Mcl-1 cooperate to protect cancer cells against apoptosis and their concomitant inhibition leads to massive apoptosis even in the absence of chemotherapy. Whereas Bcl-xL inhibitors are now available, Mcl-1 inhibition, required to sensitize cells to Bcl-xL-targeting strategies, remains problematic.
MedKoo Cat#: 406632
Chemical Formula: C29H22N4
Exact Mass: 426.18445
Molecular Weight: 426.51
Elemental Analysis: C, 81.66; H, 5.20; N, 13.14
Pyridoclax is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: Pyridoclax; MR29072; MR 29072; MR29072.
IUPAC/Chemical Name: (E)-3'-methyl-3''-styryl-3,2':5',2'':5'',3'''-quaterpyridine
InChi Key: WGGSYXQFYRWBEC-VAWYXSNFSA-N
InChi Code: InChI=1S/C29H22N4/c1-21-15-27(20-32-28(21)25-10-6-14-31-18-25)29-23(12-11-22-7-3-2-4-8-22)16-26(19-33-29)24-9-5-13-30-17-24/h2-20H,1H3/b12-11+
SMILES Code: CC1=CC(C2=NC=C(C3=CC=CN=C3)C=C2/C=C/C4=CC=CC=C4)=CN=C1C5=CC=CN=C5
The following data is based on the product molecular weight 426.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Gloaguen C, Voisin-Chiret AS, Sopkova-de Oliveira Santos J, Fogha J, Gautier F, De Giorgi M, Burzicki G, Perato S, PÃ©tigny-Lechartier C, Simonin-Le Jeune K, Brotin E, Goux D, N'Diaye M, Lambert B, Louis MH, Ligat L, Lopez F, Juin P, Bureau R, Rault S, Poulain L. First Evidence That Oligopyridines, α-Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-xL-Targeting Strategies. J Med Chem. 2015 Feb 26;58(4):1644-68. doi: 10.1021/jm500672y. Epub 2015 Feb 4. PubMed PMID: 25585174.